Kip Dudegon

Kip is an Investment Director within our healthcare team, bringing over 20 years of global experience at the intersection of biotech, pharmaceuticals and healthcare innovation.

He supports portfolio companies with commercial strategy, product development and investment planning, drawing on leadership roles across Australia, Germany and Switzerland in both operational and investment settings.

Before joining OneVentures, Kip was based in Switzerland as Senior Director of Global Commercial Brand Strategy and Marketing at Sandoz (a division of Novartis), where he led global biosimilar strategy across the US, EU and international markets. He previously held the role of Director of Global New Products in Germany, where he developed launch strategies for early stage biosimilars, including the world’s first for multiple sclerosis (natalizumab).

Earlier in his career, Kip was Head of Healthcare and Senior Investment Analyst at Magellan Financial Group in Australia, leading the firm’s healthcare sector coverage across global pharmaceutical and biotech companies. He also held commercial operations and corporate development roles at the Garvan Institute of Medical Research and worked in therapeutic antibody development at early-stage biotech companies.

Kip holds a PhD from UNSW Australia, focused on therapeutic antibody technologies, and his work has been recognised through numerous publications and patents.